Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. BPH is a benign (non-cancerous) prostate condition. Non-cancerous conditions are not usually fatal and do not spread (metastasize) to other body parts. BPH doesn't raise the risk of prostate cancer; unless it manifests symptoms, BPH isn't considered a health issue. Almost all men will have some prostate growth by the age of 70. Getting older, having more belly fat (also known as abdominal obesity), and not getting enough exercise to raise the risk of developing BPH.

The benign prostatic hyperplasic devices market  is segmented into product, procedure type, end user, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. This report offers insights and in-depth analysis of the market, emphasizing parameters, such as market trends, market dynamics, and the competitive analysis of the globally leading market players.    

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Benign Prostatic Hyperplasic Devices Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Benign Prostatic Hyperplasic Devices Market is analyzed and depicted in the report.

Benign Prostatic Hyperplasic Devices Market - Company Profiles

  • KARL STORZ SE & Co. KG
  • Richard Wolf GmbH
  • Olympus Corporation
  • Urologix, LLC.
  • Boston Scientific Corporation
  • Butterfly
  • TELEFLEX Incorporated
  • OmniGuide Holdings, Inc.
  • Convergent Laser Technologies
  • ProArc
  • Olympus Corporation    

According to the American Journal of Men's Health (AJMH), in 2019, globally, there were 11.26 million new cases and 1.86 million Years Lived with Disability (YLD) due to BPH in 2019. The incidence of BPH increased by 105.7%, and YLD increased by 110.6% worldwide during 1990–2019. The absolute incidence and YLD numbers increased considerably worldwide during this period, primarily due to population increase and aging. As per the estimates by UROLOGY FOUNDATION, in the UK, the prevalence of BPH rises from 50% among men aged 50–60 to 90% among men aged 80 and above. Some men develop sudden acute retention, i.e., the inability to pass urine. The treatment option for BPH includes surgeries such as transurethral resection of the prostate (TURP), open prostatectomy, and minimally invasive treatments such as transurethral needle ablation (TUNA). In minimally invasive treatments such as radiofrequency ablation, laser therapy, and implants, benign prostatic hyperplasic devices are used. Thus, the increase in the prevalence of benign prostatic hyperplasia and increasing risk factors are bolstering the demand for benign prostatic hyperplasic devices.  

What questions does the Benign Prostatic Hyperplasic Devices Market report answer about the regional reach of the industry

The report claims to split the regional scope of the Benign Prostatic Hyperplasic Devices Market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

  • How do the sales figures look at present How does the sales scenario look for the future
  • Considering the present scenario, how much revenue will each region attain by the end of the forecast period
  • How much is the market share that each of these regions has accumulated presently
  • How much is the growth rate that each topography will depict over the predicted timeline

Product Insights

Based on the product, the benign prostatic hyperplasic devices market is segmented into resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. The resectoscopes segment is likely to hold the largest market share in 2022. However, the urology lasers segment is anticipated to register the highest CAGR during the forecast period due to the high demand by physicians and the rising initiatives of market players in the launch and product expansion.

Procedure Type Insights

Based on procedure type, the benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. In 2022, the transurethral resection of the prostate segment is likely to hold the market's largest share. Furthermore, the same segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to its visual, hands-on access to the prostate, ability to immediate removal of excess tissue, the ability of transurethral resection of the prostate (TURP) to combine with other procedures.

End User Insights

Based on end user, the benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment is likely to hold the largest share of the market. Moreover, the clinics segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to an increase in the number of clinics at a lower cost for treatment, easy accessibility, and flexibility with the short waiting time.

 About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876